SMTI - Sanara MedTech Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Sanara MedTech Inc.

1200 Summit Avenue
Suite 414
Fort Worth, TX 76102
United States
817-529-2300
http://www.wndm.com

SectorHealthcare
IndustryMedical Care
Full Time Employees19

Key Executives

NameTitlePayExercisedYear Born
Mr. J. Michael CarmenaVice Chairman & Principal Exec. Officer207.11kN/A1956
Mr. Michael D. McNeilChief Financial Officer178.76kN/A1966
Mr. Ronald T. NixonExec. ChairmanN/AN/A1956
Mr. Callon NicholsDirector of Investor RelationsN/AN/AN/A
Dr. Jane A. ForeChief Medical OfficerN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sanara MedTech Inc. develops, markets, and distributes biotechnology products to physicians, hospitals, and clinics in the United States. It offers HemaQuell, a resorbable bone hemostat for bone healing; and CellerateRX surgical for healing. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was founded in 1982 and is based in Fort Worth, Texas.

Corporate Governance

Sanara MedTech Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.